CARIS LIFE SCIENCES, INC. Deferred Offering Costs
CARIS LIFE SCIENCES, INC. (CAI) had Deferred Offering Costs of $4.50 million as of 2024-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-03-03
- 2024-12-31: Deferred Offering Costs $4.50M.
| Period end | Deferred Offering Costs |
|---|---|
| 2024-12-31 | $4.50M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |